IMNM - Company ID 0001472012
The table below shows Immunome Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$190.92M | -$110.79M | -$7.57M | -$28.69M | -$18.23M | -$12.13M |
| Capital expenditure | $9.69M | $7.17M | $831.00K | $248.00K | $79.00K | $586.00K |
| Investing cash flow | $60.80M | -$85.06M | -$30.48M | -$248.00K | -$79.00K | -$586.00K |
| Dividends paid | - | - | - | - |
Immunome Inc. reported operating cash flow of -$190.92M for fiscal year 2025. That is down 72.3% from -$110.79M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$9.60M (FY 2019) to -$190.92M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $640.36M | $240.53M | $116.41M | $32.00K | $27.77M | $49.94M |